双靶抑制EGFR与VEGF通路:EGFR突变NSCLC的治疗新策略
本文综述了EGFR突变NSCLC中EGFR与VEGF通路交互作用的临床前与临床证据。临床前研究显示EGFR信号上调可通过缺氧非依赖机制增加VEGF,而VEGF升高促进EGFR-TKI耐药。近期大型随机研究显示,在TKI初治EGFR突变NSCLC中,贝伐珠单抗或雷莫芦单抗联合EGFR-TKI可显著改善无进展生存期。
要点
- EGFR与VEGF通路共享下游信号且可独立驱动肿瘤发生。
- EGFR突变NSCLC中VEGF升高参与EGFR-TKI耐药。
- TKI初治患者中抗VEGF联合EGFR-TKI显著改善PFS。
核心结论
- 临床前与临床数据支持在EGFR突变NSCLC中双靶抑制EGFR和VEGF以改善患者结局。
研究设计与样本
- 本文为综述,汇总EGFR突变NSCLC中双靶抑制EGFR与VEGF的临床前与临床数据。
主要发现
- 临床前研究发现VEGF与EGFR通路共享下游信号,且可在肿瘤发生中独立发挥作用。
- EGFR突变NSCLC中上调的EGFR信号通过缺氧非依赖机制增加VEGF,升高的VEGF促进EGFR-TKI耐药产生。
- 临床试验中,在EGFR-TKI基础上加用抗VEGF治疗显著改善临床结局。
- 近期大型随机研究中,在TKI初治EGFR突变NSCLC患者中加用贝伐珠单抗或雷莫芦单抗至EGFR-TKI大幅改善无进展生存期。
临床怎么用
- 对TKI初治EGFR突变NSCLC患者,可考虑EGFR-TKI联合抗VEGF药物(如贝伐珠单抗或雷莫芦单抗)以改善无进展生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the VEGF and EGFR pathways share common downstream signaling, and these pathways can function exclusively of one another during oncogenesis. In EGFR-mutant NSCLCs, up-regulated EGFR signaling increases VEGF through hypoxia-independent mechanisms, and elevated VEGF, in turn, contributes to the emergence of resistance to EGFR tyrosine kinase inhibitors (TKIs). In clinical trials, the addition of anti-VEGF therapy to EGFR TKIs considerably improved clinical outcomes. In recently reported large randomized studies, the addition of bevacizumab or ramucirumab to EGFR TKIs substantially improved progression-free survival in patients with TKI-naive EGFR-mutant NSCLC. This article reviews the preclinical and clinical data supporting dual inhibition of EGFR and VEGF in EGFR-mutant NSCLC as a way to improve patient outcomes.
引用
- Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. J Thorac Oncol. 2020. PMID: 33096270. doi:10.1016/j.jtho.2020.10.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。